Ciba turns down Biosignal compounds
Wednesday, 06 August, 2008
Global specialty chemical company Ciba Corporation has decided to stop testing Biosignal's [ASX: BOS] anti-microbial industrial compounds, citing major issues incorporating the product into theirs.
Ciba was evaluating whether it could incorporate the compounds into its PVC plastic and coatings, but found that doing so resulted in high temperatures during the processing stage and incompatibility with other components.
Representatives for Biosignal said the decision did not alter expectations for the viability of the compounds, stating that it still had evaluation agreements in place with a number of companies.
These include oil producer ConocoPhillips, sanitation product manufacturers Saraya Co, and leading agrichemicals and animal health companies.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
